Chester County News and Community Website
MALVERN, PA — In a significant advancement for retinitis pigmentosa (RP) treatment, Ocugen, Inc. (NASDAQ: OCGN) has received favorable scientific advice from the European Medicines Agency (EMA) regarding its pivotal …
Ocugen’s Gene Therapy OCU400 Moves Closer to European Market with EMA’s Positive Opinion Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company at the forefront of gene therapy innovation, has recently announced a groundbreaking development in the fight against retinitis pigmentosa (RP), …
Ocugen’s Leap into Phase 3 Trials: A Beacon of Hope for Retinitis Pigmentosa Patients Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focusing on discovering, developing, and commercializing transformative therapies to cure blindness diseases, announced a significant milestone in its Phase 1/2 …
Ocugen Advances in Pioneering Gene Therapy for Geographic Atrophy with DSMB Approval to Proceed to Medium Dose in Clinical Trial Read More MALVERN, PA — Ophthalmology is on the crest of a wave; a paradigm shift heralded by Ocugen, Inc (NASDAQ: OCGN) may be imminent. The Pennsylvania-based biopharmaceutical firm recently crossed a …
Ocugen’s Revolutionary Gene Therapy Targets Geographic Atrophy: A Shift in Ophthalmology on the Horizon Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN), a pioneer in the biotechnology field, is set to hold an in-person Clinical Showcase on February 21, 2024, at the Nasdaq Market Site …
Ocugen to Spotlight Promising Gene Therapy in Clinical Showcase Read More MALVERN, PA — Biopharmaceutical company Ocugen, Inc. (NASDAQ: OCGN) has announced the commencement of its Phase 1/2 GARDian clinical trial for OCU410ST (AAV5-hRORA), a gene therapy candidate being developed to …
Ocugen Initiates Phase 1/2 GARDian Clinical Trial for Stargardt Disease Therapy Read More